References
Hutchinson TA, Flegel KM, Kramer MS, Leduc DG, Kong HH. Frequency, severity, and risk factors for adverse drug 19 reactions in adult outpatients: a prospective study. J Chronic Disease 1986; 39: 533–542.
Williamson J, Chopin JM. Adverse reactions to prescribed drugs in the elderly: a multicentre investigation. Age Ageing 1980; 9: 73–80.
Kellaway GS, McCrae E. Intensive monitoring for adverse drug effects in patients discharged from acute medical wards. New Zealand Med J 1973; 78: 525–528.
Smith JW, Seidl LG, Cluff LE. Studies on the epidemiology of adverse drug reactions V. Clinical factors influencing susceptibility. Ann Int Med 1966; 65: 629–640.
Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann Int Med 1991; 114: 956–966.
Darnell JC, Murray MD, Martz BL, Weinberger M. Medication use by ambulatory elderly. An in-home survey. J Am Geriatr Soc 1986; 34: 1–4.
Spagnoli A, Ostino G, Borga AD et al. Drug compliance and unreported drugs in the elderly. J Am Geriatr Soc 1989; 37: 619–624.
Mitchell GW, Stanaszek WF, Nichols NB. Documenting drug-drug interactions in ambulatory patients. Am J Hosp Pharm 1979; 36: 653–657.
Armstrong WA, Driever CW, Hays RL. Analysis of drug-drug interactions in a geriatric population. Am J Hosp Pharm 1980; 37: 385–387.
Cadieux RJ. Drug interactions in the elderly. How multiple drug use increases risk exponentially. Post-Grad Med 1989; 86: 179–186.
Costa AJ. Potential drug interactions in an ambulatory geriatric population. Fam Pract 1991; 8: 234–236.
Doucet J, Chassagne P, Trivalle C, Landrin I, Pauty MD, Kadri N, Menard JF, Bercott E. Drug-drug interactions related to hospital admissions in older adults: A prospective study of 1000 patients. J Am Geriatr Soc 1996; 44: 944–948.
Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 1950; 29: 496–507.
Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278–285.
Cusack B, Kelly J, O'Malley K, Noel J, Lavan J, Horgan J. Digoxin in the elderly: pharmacokinetic consequences of old age. Clin Pharmacol Ther 1979; 25: 772–776.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41.
George J, Byth K, Farrell GC. Age but not gender selectively affects expression of individual cytochrome P-450 proteins in human liver. Biochem Pharmacol 1995; 50: 727–730.
Greenblatt DJ, Divoll M, Abernethy DR, Moschitto U, Smith RB, Shader RI. Reduced clearance of triazolam in old age: Relation to antipyrine oxidizing capacity. Brit J Clin Pharmacol 1983; 15: 303–309.
Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984; 61: 27–35.
Greenblatt DJ, Shader RI, Abernethy DR. Drug therapy: current status of benzodiazepines. N Engl J Med 1983; 309: 354–358, 410-416.
Greenblatt DJ, Allen MD, Shader RI. Toxicity of high-dose flurazepam in the elderly. Clin Pharmacol Ther 1977; 21: 355–361.
Ray WA, Griffin MR, Schaffaer W, Baugh DK, Melton LJ. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316: 363–369.
Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. J Am Med Assoc 1989; 262: 3303–3307.
Reidenberg MM, Levy M, Warner H et al. Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clin Pharmacol Ther 1978; 23: 371–374.
Smith JM, Baldessarini RJ. Changes in prevalence, severity and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 1980; 37: 1368–1373.
Moleman P, Janzen G, von Bargen BA, Kappers EJ, Pepplinkhuizen L, Schmitz PIM. Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol. Am J Psychiatry 1986; 143: 232–234.
Shepherd AM, Hewick DS, Moreland TA et al. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol 1977; 4: 315–320.
Gurwitz JH, Goldberg RJ, Holden A, Knapic N, Ansell J. Agerelated risks of long-term oral anticoagulant therapy. Arch Int Med 1988; 148: 1733–1736.
Petitti DB, Strom BL, Melmon KL. Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage. Am J Med 1986; 81: 255–259.
Vestal RE, Wood AJJ, Shand DG. Reduced beta-adrenoceptor sensitivity in the elderly. Clin Pharmacol Ther 1979; 26: 181–186.
Pan HYM, Hoffman BB, Porshe RA, Blaschke TF. Decline in beta-adrenergic receptor-mediated vascular relaxation with aging in man. J Pharmacol Exp Ther 1986; 239: 802–807.
Scarpace PJ. Decreased β-adrenergic responsiveness during senescense. Fed Proc 1986; 45: 51–54.
Montamat SC, Davies AO. Physiological response to isoproterenol and coupling of beta-adrenergic receptors in young and elderly human subjects. J Gerontol 1989; 44: M100–M105.
White M, Roden R, Minobe W, Khan MF, Larrabee P, Wollmering M, Port JD, Anderson F, Campbell D, Feldman AM, Bristow MR. Age-related changes in β-adrenergic neuroeffector systems in the human heart. Circulation 1994; 90: 1225–1238.
Abernethy DR, Schwartz JB, Plachetka JR, Todd EL, Egan JM. Comparison in young and elderly patients of pharmacodynamics and disposition of labetalol in systemic hypertension. Am J Cardiol 1987; 60: 697–702.
Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Fasolo CB, Sudano I, Salvetti A. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995; 91: 1981–1987.
Jones D, Andrawis NS, Abemethy DR. Aging is associated with altered vascular reactivity to angiotensin II (AII) and acetylcholine (ACH). (abstract) Clin Pharmacol Ther 1998; 63: 174.
Zeiher AM, Drexter H, Saurbier B, Just H. Endotheliummediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993; 92: 652–662.
Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelium-dependent coronary vasomotor responsiveness in post-menopausal women with and without estrogen replacement therapy. Am J Cardiol 1994; 73: 951–952.
Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, Brinker JA. Estradiol acutely attenuates coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994; 89: 52–60.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Abernethy, D.R. Aging effects on drug disposition and effect. Geriatric Nephrology and Urology 9, 15–19 (1999). https://doi.org/10.1023/A:1008333511884
Issue Date:
DOI: https://doi.org/10.1023/A:1008333511884